APREA
Aprea is a biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea Therapeutics was established in 2003 in Stockholms Lan, Sweden by Klas Wiman and Galina Selivanova.
APREA
Industry:
Biotechnology Health Care Medical Personal Health Pharmaceutical
Founded:
2003-01-01
Address:
Stockholm, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.aprea.com
Total Employee:
1+
Status:
Active
Contact:
+460850884504
Total Funding:
136.37 M USD
Technology used in webpage:
Domain Not Resolving Apple Mobile Web Clips Icon Content Delivery Network JsDelivr Nginx COVID-19 Gravity Forms Akamai Hosted Nginx 1.10 Formidable Pro Form
Similar Organizations
AEON Biopharma
AEON Biopharma is a biopharmaceutical company that develops novel and proprietary treatment paradigms to improve patient outcomes.
AstraZeneca
AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Cellectis
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Medivir
Medivir is a research-based pharmaceutical company with a research focus on oncology and infectious diseases.
Novartis
Novartis is a healthcare company that provides solutions to address the evolving needs of patients worldwide.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Sprout Pharmaceuticals
Sprout Pharmaceuticals is a medical company that develops products for the treatment of female sexual dysfunction.
Current Employees Featured
Christian Schade President and chief executive officer @ Aprea
President and chief executive officer
2016-06-01
Lars Abrahmsen Senior vice-president and chief scientific officer @ Aprea
Senior vice-president and chief scientific officer
2014-10-01
Scott Coiante Senior Vice President & Chief Financial Officer @ Aprea
Senior Vice President & Chief Financial Officer
2019-08-01
Gregory Korbel Senior Vice President & Chief Business Officer @ Aprea
Senior Vice President & Chief Business Officer
2021-03-01
Richard Peters Director @ Aprea
Director
2020-06-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-05-16 | Atrin Pharmaceuticals | Atrin Pharmaceuticals acquired by Aprea | N/A |
Investors List
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - Aprea
Nantahala Capital Management
Nantahala Capital Management investment in Post-IPO Equity - Aprea
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Post-IPO Equity - Aprea
Exome Asset Management
Exome Asset Management investment in Post-IPO Equity - Aprea
Stonepine Capital Management
Stonepine Capital Management investment in Post-IPO Equity - Aprea
National Cancer Institute
National Cancer Institute investment in Grant - Aprea
Keiretsu Capital
Keiretsu Capital investment in Post-IPO Equity - Aprea
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Aprea
Redmile Group
Redmile Group investment in Series C - Aprea
Karolinska
Karolinska investment in Series C - Aprea
Official Site Inspections
http://www.aprea.com Semrush global rank: 5.01 M Semrush visits lastest month: 1.65 K
- Host name: 172.67.162.53
- IP address: 172.67.162.53
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Aprea"
Aprea Therapeutics Board of Directors
Jean-Pierre Bizzari, M.D., joined the Aprea Board in August 2023 with a remarkable and distinguished career in oncology. He has been responsible for numerous global approvals of …See details»
Aprea Therapeutics | DDR-Targeted Therapy
Aprea Therapeutics embraces the latest advancements in precision medicine and targeted therapies. Our approach focuses on matching treatments to specific cancer-related genetic …See details»
Aprea Therapeutics Management Team
Aprea’s executive management team, Board of Directors, and scientific founders are unified by their dedication to developing groundbreaking, precision therapeutics for patients with …See details»
Aprea - Funding, Financials, Valuation & Investors - Crunchbase
May 16, 2022 Aprea is registered under the ticker NASDAQ:APRE . Their stock opened with $15.00 in its Oct 2, 2019 IPO. Aprea is funded by 17 investors. Dafna Capital Management …See details»
Aprea - Recent News & Activity - Crunchbase
Edit Recent News & Activity Section. Funding Round • Mar 11, 2024 • Mar 11, 2024See details»
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 …
21 hours ago Aprea Therapeutics. ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025See details»
Aprea Therapeutics Company Profile - Office Locations ... - Craft
Oct 29, 2024 Aprea Therapeutics is a pharmaceutical development company that is engaged in the discovery and development of anticancer compounds targeting tumour suppressor …See details»
Aprea Therapeutics Announces Agreement with MD Anderson …
Mar 11, 2025 Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast …See details»
Aprea Therapeutics - businessabc
Mar 7, 2025 Aprea Therapeutics was founded in 2008 with a mission to develop anticancer compounds that specifically target tumor suppressing proteins. The company has since …See details»
Aprea Therapeutics, Inc. (APRE) - Yahoo Finance
See the company profile for Aprea Therapeutics, Inc. (APRE) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Aprea Therapeutics - Overview, News & Similar companies
Who is Aprea Therapeutics. Aprea Therapeutics acquired privately held Atrin Pharmaceuticals in May 2022. Aprea has made the assets and technology acquired from Atrin a key fo cus …See details»
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 …
1 day ago DOYLESTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company …See details»
Aprea Therapeutics | Leaders in DDR-Targeted Solutions
Aprea Therapeutics acquired privately held Atrin Pharmaceuticals in May 2022 and has moved ATRN-119 and APR-1051 forward. Join Aprea’s Mission Join in our quest to develop cutting …See details»
Aprea Therapeutics Launches New Corporate Website
BOSTON, April 06, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer …See details»
APREA - Crunchbase Company Profile & Funding
APREA is a non profit organization that provides advisory services to real assets sector of Asia Pacific region.See details»
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 …
1 day ago Aprea engaged Philippe Pultar, MD in October 2024 as senior medical advisor to support the development and advancement of APR-1051. Dr. Pultar is a seasoned …See details»
Aprea Therapeutics Announces Agreement with MD Anderson …
Mar 11, 2025 Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast …See details»
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in …
Feb 5, 2025 Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast …See details»
Aprea Therapeutics Launches New Corporate Website
Jun 4, 2020 Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and …See details»
Annual Report (2020 Highlights Letter from CEO) - APREA Asia
Sigrid brings to APREA more than 20 years of experience in economic and real estate research, consulting and business strategy. From 2010 through 2018, she served as Managing Director …See details»